Approximately 20% Higher Yield: The FDA Approval for the Innovative Production Process Causes the Biotech ADMA Biologics to Break out.

ADMA Biologics (ADMA) is a leading stock in recent quarters. It is a biopharmaceutical company specializing in plasma-based therapeutics for the treatment ofimmune deficiency diseases and infections. The company operates its own plasma collection centers and production facilities and sells its products primarily in the USA. ADMA offers several FDA-approved IVIG products and is well-positioned in the rapidly growing immunoglobulin market. Using the ADMAlytics AI platform, the company optimizes its production processes, commercial planning, and specifically...